https://openbell.ai/ 2026-10-26T18:38:40.498Z hourly 1.0 https://openbell.ai/support 2026-10-26T18:38:40.498Z monthly 0.7 https://openbell.ai/privacy 2026-10-26T18:38:40.498Z monthly 0.5 https://openbell.ai/terms 2026-10-26T18:38:40.498Z monthly 0.5 https://openbell.ai/feed.json 2026-10-26T18:38:40.498Z hourly 0.8 https://openbell.ai/news/MIRM:1793037751000 2026-10-26T18:02:31.000Z daily 0.9 https://cdn.brandfetch.io/MIRM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mirum Pharmaceuticals Reports Positive Phase 2 PROGRESS Study Results for ATEBRIOZ in Children with FOP Mirum Pharmaceuticals reported positive 24-week results from the second cohort of its Phase 2 PROGRESS study of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. Bone lesion volume decreased by 8.09 cm³ among treated patients, compared with a 9.14 cm³ increase with placebo; treated patients also showed improved joint mobility, no new lesions, and no new safety signals. Mirum plans to submit a supplemental New Drug Application to the FDA in the first half of 2027 to seek approval for use in this younger age group. https://openbell.ai/news/SOBO:1793037749000 2026-10-26T18:02:29.000Z daily 0.9 https://cdn.brandfetch.io/SOBO/w/400/h/400?c=1idopYfmtR7ZKg8QMud South Bow Corporation Reports Spring Quarter Profit Growth and Provides Prairie Connector Update South Bow Corporation reported spring-quarter profit of US$134 million, up nearly 40% from the same period last year. Its proposed Prairie Connector pipeline has secured customer commitments for 465,000 barrels per day over 20 years and would use existing infrastructure from the cancelled Keystone XL project to transport crude to U.S. markets. South Bow is targeting a final investment decision by mid-2027, subject to obtaining the required regulatory permits. https://openbell.ai/news/WCN:1793037741000 2026-10-26T18:02:21.000Z daily 0.9 https://cdn.brandfetch.io/WCN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Waste Connections Reports Q3 2026 Financial Results Waste Connections reported third-quarter 2026 results that exceeded analyst expectations for revenue and non-GAAP profit. Management cited core pricing, solid waste margin expansion, and improved landfill volumes as drivers of performance. The stock reached a 52-week high of $260.95 on the Toronto Stock Exchange on October 26, 2026. https://openbell.ai/news/CMI:1793037740000 2026-10-26T18:02:20.000Z daily 0.9 https://cdn.brandfetch.io/CMI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cummins Announces Multiyear Hyperscaler Supply Agreement and Raises 2026 Revenue Outlook Cummins CEO Jennifer Rumsey announced a multiyear supply agreement with a hyperscaler, backed by expanded manufacturing capacity. The company raised its 2026 revenue growth outlook to 10%–13%. Management also clarified the timing of upcoming EPA emissions regulations, anticipating a staggered engine rollout through 2027. https://openbell.ai/news/CORT:1793037738000 2026-10-26T18:02:18.000Z daily 0.9 https://cdn.brandfetch.io/CORT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Corcept Therapeutics Announces Positive Phase 2 BELLA Trial Results for Lifyorli Combination in Ovarian Cancer Corcept Therapeutics reported positive Phase 2 BELLA trial results for Lifyorli combined with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer. The regimen achieved median progression-free survival of 7.2 months and an objective response rate of 59%; 88% of patients were alive at the six-month overall-survival timepoint. The results mark a clinical update for Corcept’s oncology development program; the article did not report financial results or a stock-price reaction. https://openbell.ai/news/PEN:1793037733000 2026-10-26T18:02:13.000Z daily 0.9 https://cdn.brandfetch.io/PEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Penumbra, Inc. Announces Positive Clinical Results from BOLT-DVT Trial Penumbra reported positive results from its BOLT-DVT IDE clinical trial, with a 98% thrombus removal rate and a 3.1% major adverse event rate at 48 hours. At 30 days, 84.3% of treated patients were free of post-thrombotic syndrome; patients also reported immediate, sustained pain relief and improved quality of life on the VEINES-QOL measure. The article did not report financial results or a stock-price reaction. https://openbell.ai/news/JAZZ:1793037723000 2026-10-26T18:02:03.000Z daily 0.9 https://cdn.brandfetch.io/JAZZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jazz Pharmaceuticals' ZIIHERA Receives Regulatory Approvals for Biliary Tract Cancer Jazz Pharmaceuticals and its partners received U.S. accelerated approval and EU conditional marketing authorization for ZIIHERA (zanidatamab-hrii) for eligible patients with biliary tract cancer. The drug is licensed from Zymeworks. Jazz is also conducting the Phase 3 HERIZON-GEA-01 trial, testing ZIIHERA with chemotherapy as a first-line treatment for advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The article reports no financial results or stock-price impact. https://openbell.ai/news/BA:1793037700000 2026-10-26T18:01:40.000Z daily 0.9 https://cdn.brandfetch.io/BA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Boeing Awarded $930.77 Million US Navy Contract for Super Hornet Upgrades Boeing received a $930.77 million U.S. Navy contract to continue its Super Hornet Service Life Modification program. The work is intended to extend the service life of up to 60 F/A-18E/F aircraft from 6,000 to 10,000 flight hours and includes provisions to upgrade older aircraft to the Block III standard. The article does not report a stock-price impact. https://openbell.ai/news/RECI:1793035928000 2026-10-26T17:32:08.000Z daily 0.9 https://cdn.brandfetch.io/RECI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Real Estate Credit Investments Ltd. Delays Interim Financial Results and Continues Restructuring Real Estate Credit Investments Ltd. said it could not publish interim results for the six months ended June 30, 2026, by the required deadline. The Board is pursuing restructuring and deleveraging initiatives and engaging with lenders, but these efforts remain subject to material uncertainties and approvals. Given the company’s financial position and the priority of creditor claims, the Board said prospects for recovery by ordinary shareholders are extremely limited. https://openbell.ai/news/AVCT:1793035923000 2026-10-26T17:32:03.000Z daily 0.9 https://cdn.brandfetch.io/AVCT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Avacta Reports Positive Phase 1a/1b Data for Faridoxorubicin in Salivary Gland Cancer Avacta Group reported updated Phase 1a/1b trial data for faridoxorubicin (AVA6000), showing median progression-free survival of 11.4 months in a defined subset of patients with salivary gland cancer, compared with historical benchmarks of 6 to 6.7 months. The company also reported clinically meaningful tumor shrinkage in most patients in the subset. Avacta said the results support the potential of its pre|CISION platform to target drug payloads to tumors while limiting systemic toxicity. https://openbell.ai/news/ASND:1793034120000 2026-10-26T17:02:00.000Z daily 0.9 https://cdn.brandfetch.io/ASND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ascendis Pharma Announces Positive Long-Term Data for TransCon PTH in Hypoparathyroidism Ascendis Pharma reported pooled Phase 2 and Phase 3 data showing TransCon PTH (palopegteriparatide) was associated with statistically significant improvements in kidney function and normalized 24-hour urine calcium in adults with hypoparathyroidism, sustained for up to five years. At the final trial visit, 98% of patients were independent of active vitamin D and 95% were independent of therapeutic calcium doses. The results were presented at Kidney Week 2026; the article did not report financial results or a stock-price reaction. https://openbell.ai/news/ALLEI:1793034116000 2026-10-26T17:01:56.000Z daily 0.9 https://cdn.brandfetch.io/ALLEI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alleima Reports Third Quarter 2026 Financial Results Alleima reported its financial results for the third quarter and first nine months ended September 30, 2026. Adjusted operating profit for the period was below market expectations. The article provides no specific financial figures or stock-price impact.